Marie Claxton

Marie Claxton serves as a key procurement professional within the CDC Office of Acquisition Services, supporting the agency’s mission to safeguard public health through strategic acquisition of critical scientific and diagnostic capabilities. She manages a diverse portfolio of contracts focused on laboratory instrumentation, in-vitro diagnostic substances, and data infrastructure essential for disease surveillance and rapid response operations. Her work ensures timely access to high-performance analytical tools and clinical testing platforms that underpin national public health preparedness, with a strong emphasis on mission-critical, science-driven procurements aligned with CDC’s operational priorities. Claxton maintains longstanding partnerships with leading providers in biomedical and public health technology, including General Dynamics Information Technology, GlaxoSmithKline, Cepheid, MRIGLOBAL, and the New York City Health & Hospitals Corp. These relationships reflect a preference for established industry leaders with proven capabilities in diagnostic manufacturing, laboratory services, and data systems integration. Her contracting approach prioritizes technical excellence, regulatory compliance, and supply chain reliability, often engaging vendors with deep expertise in FDA-regulated products and CLIA-certified testing environments. Her procurement portfolio shows no reliance on socioeconomic set-asides, with 100% of awards issued under full and open competition. This reflects a strategic focus on securing the highest-capability solutions available in the market, regardless of vendor size or certification status, consistent with CDC’s need for rapid, scalable, and technically robust capabilities during public health emergencies. Claxton’s primary procurement focus lies in NAICS 334516 (analytical laboratory instruments) and 325413 (in-vitro diagnostic substances), complemented by significant activity in medical laboratories (621511) and computing infrastructure services (518210). She specializes in acquiring advanced molecular diagnostics, automated testing platforms, and secure data processing systems that enable real-time epidemiological analysis and laboratory network coordination across the nation’s public health infrastructure.